Literature DB >> 18447000

On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells.

Adam J Shuhendler1, Peter J O'Brien, Andrew M Rauth, Xiao Yu Wu.   

Abstract

The combination of doxorubicin and mitomycin C has been shown previously to result in supra-additive tumor cell killing in vitro in both murine and human breast cancer cells and in vivo against murine breast cancer cells. Median effect analysis was used to determine the significance and degree of interaction. The origin of this synergy was sought by evaluating the contribution of membrane efflux pump modulation, formaldehyde production, reactive oxygen species, DNA cross-linking, and DNA double-strand breaks to this effect. The interaction of mitomycin C and doxorubicin in vitro was found to be a true synergy whose mechanism was efflux pump-independent. DNA cross-links were only found to increase additively with co-administration of the drugs; however, a supra-additive increase in DNA double-strand breaks was observed. The results suggest that poisoning of topoisomerase IIalpha by doxorubicin may interact with drug-induced DNA cross-links to enhance the formation of DNA double-strand breaks. This interaction, together with glutathione depletion and mitomycin C-derived formaldehyde, may be the underlying mechanism(s) of the synergy observed between mitomycin C and doxorubicin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18447000     DOI: 10.1515/dmdi.2007.22.4.201

Source DB:  PubMed          Journal:  Drug Metabol Drug Interact        ISSN: 0792-5077


  9 in total

1.  A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells.

Authors:  Preethy Prasad; Ji Cheng; Adam Shuhendler; Andrew M Rauth; Xiao Yu Wu
Journal:  Drug Deliv Transl Res       Date:  2012-04       Impact factor: 4.617

2.  Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.

Authors:  R B Raffa; R J Tallarida
Journal:  J Clin Pharm Ther       Date:  2010-06       Impact factor: 2.512

3.  Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.

Authors:  Rui Xue Zhang; Tian Zhang; King Chen; Ji Cheng; Paris Lai; Andrew M Rauth; K Sandy Pang; Xiao Yu Wu
Journal:  J Vis Exp       Date:  2017-10-05       Impact factor: 1.355

Review 4.  Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.

Authors:  Rui Xue Zhang; Ho Lun Wong; Hui Yi Xue; June Young Eoh; Xiao Yu Wu
Journal:  J Control Release       Date:  2016-06-08       Impact factor: 9.776

Review 5.  Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples.

Authors:  Rui Xue Zhang; Jason Li; Tian Zhang; Mohammad A Amini; Chunsheng He; Brian Lu; Taksim Ahmed; HoYin Lip; Andrew M Rauth; Xiao Yu Wu
Journal:  Acta Pharmacol Sin       Date:  2018-04-26       Impact factor: 6.150

Review 6.  Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance?

Authors:  Marta Szumilak; Anna Wiktorowska-Owczarek; Andrzej Stanczak
Journal:  Molecules       Date:  2021-04-29       Impact factor: 4.411

Review 7.  Pharmaceutical nanoformulation strategies to spatiotemporally manipulate oxidative stress for improving cancer therapies - exemplified by polyunsaturated fatty acids and other ROS-modulating agents.

Authors:  Rui Xue Zhang; Franky Fuh-Ching Liu; Hoyin Lip; Junhong Liu; Qianrong Zhang; Xiao Yu Wu
Journal:  Drug Deliv Transl Res       Date:  2022-01-22       Impact factor: 5.671

8.  Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.

Authors:  Tian Zhang; Preethy Prasad; Ping Cai; Chunsheng He; Dan Shan; Andrew Michael Rauth; Xiao Yu Wu
Journal:  Acta Pharmacol Sin       Date:  2017-02-20       Impact factor: 6.150

9.  Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy.

Authors:  Alberto Gabizon; Patricia Ohana; Yasmine Amitay; Jenny Gorin; Dina Tzemach; Lidia Mak; Hilary Shmeeda
Journal:  Cancer Drug Resist       Date:  2021-06-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.